We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Illumina

Illumina develops, manufactures and markets integrated systems for the analysis of genetic variations and biological ... read more Featured Products: More products

Download Mobile App




New Genetic Disease Identified in Children

By LabMedica International staff writers
Posted on 09 Apr 2014
A new genetic disease that causes neurologic, muscle, eye and liver problems in children has been identified by a combination of modern gene-sequencing techniques. More...


Mutations in the gene coding for N-glycanase 1 (NGLY1), an enzyme that recycles defective products from a cellular assembly line, was found in children who have varying degrees of movement disorders, including a characteristic combination of muscle contractions that causes abnormal tremulous movements.

Scientists at Lucile Packard Children’s Hospital (Palo Alto, CA, USA) and an international team of collaborators found eight children who through case reports and social media had clinical symptoms similar to an initial case and were found in a matter of months. All patients had global developmental delay, a movement disorder, and hypotonia. Other common findings included hypolacrima or alacrima (7/8), electroencephalography (EEG) abnormalities (7/8), elevated liver transaminases (6/7), microcephaly (6/8), abnormal brain imaging (6/8), diminished reflexes (6/8).

Exome sequencing was performed in the different collaborating laboratories using the HiSeq2000 platform (Illumina; San Diego, CA, USA) and the SureSelect Human All Exon 50 Mb Kit (Agilent; Santa Clara CA, USA) and for all patients, variants were confirmed by Sanger sequencing. The nonsense mutation c.1201A>T (p.R401X) was the most common deleterious allele identified, present in the homozygous state in five of eight cases and in the compound heterozygous state in one case. Two patients did not carry the c.1201A>T (p.R401X) mutation and their clinical phenotype was relatively mild by comparison.

The study confirmed that children with a defective NGLY1 gene do not make the N-glycanase enzyme. The scientists also observed that the children's liver biopsies contained an amorphous substance, which they suspected was an accumulation of protein that did not get recycled. Gregory Enns, MB, ChB, an associate professor of genetics in pediatrics and co-lead author, said, “This represents a complete change in the way we're going about clinical medicine. This is happening so quickly because of the integration of the families with the scientists, and because so many people are coming at this from so many angles.” The study was published on March 20, 2014, in the journal Genetics in Medicine.

Related Links:

Lucile Packard Children’s Hospital
Illumina
Agilent



Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
Drug Test Kit
DrugCheck 3000
New
PlGF Test
Quidel Triage PlGF Test
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: An “evolutionary” approach to treating metastatic breast cancer could allow therapy choices to be adapted as patients’ cancer changes (Photo courtesy of 123RF)

Evolutionary Clinical Trial to Identify Novel Biomarker-Driven Therapies for Metastatic Breast Cancer

Metastatic breast cancer, which occurs when cancer spreads from the breast to other parts of the body, is one of the most difficult cancers to treat. Nearly 90% of patients with metastatic cancer will... Read more

Pathology

view channel
Image: A real-time trial has shown that AI could speed cancer care (Photo courtesy of Campanella, et al., Nature Medicine)

AI Accurately Predicts Genetic Mutations from Routine Pathology Slides for Faster Cancer Care

Current cancer treatment decisions are often guided by genetic testing, which can be expensive, time-consuming, and not always available at leading hospitals. For patients with lung adenocarcinoma, a critical... Read more

Technology

view channel
Image: Researchers Dr. Lee Eun Sook and Dr. Lee Jinhyung examine the imprinting equipment used for nanodisk synthesis (Photo courtesy of KRISS)

Multifunctional Nanomaterial Simultaneously Performs Cancer Diagnosis, Treatment, and Immune Activation

Cancer treatments, including surgery, radiation therapy, and chemotherapy, have significant limitations. These treatments not only target cancerous areas but also damage healthy tissues, causing side effects... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.